Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial

Marina Konopleva, MD, presents a subanalysis of a pivotal trial evaluating tagraxofusp in treatment-naïve BPDCN, demonstrating its potent anti-tumor activity, rapid clearance of peripheral blasts, and restoration of normal hematopoiesis without cumulative myelosuppression.